Proton pump inhibitor use and long-term outcomes in systemic sclerosis: a real-life analysis from the EUSTAR database

Clicks: 17
ID: 329203
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #198 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To investigate the association between proton pump inhibitor (PPI) use, all-cause mortality, and interstitial lung disease (ILD) progression in systemic sclerosis (SSc). METHODS: SSc patients enrolled in the EUSTAR registry with at least two clinical visits were included (EUSTAR CP141). PPI exposure was modeled as a time-varying variable. Inverse probability of treatment weighting (IPTW) based on propensity scores was applied to address confounding by indication. All-cause mortality was analysed using IPTW-weighted time-varying Cox models. ILD progression was assessed using functional endpoints (FVC decline ≥10% and ≥5%; DLCO decline ≥10%). Restricted mean survival time (RMST) was used to quantify absolute effects. Sensitivity analyses included a 6-month lag time. RESULTS: Out of 10,660 patients enrolled, 8,637 (81.0%) were exposed to PPIs during a mean follow-up of 5.7 ± 4.3 years. They exhibited a more severe multisystem disease phenotype, including greater gastrointestinal, pulmonary, and vascular involvement. After adjustment, PPI exposure was associated with higher all-cause mortality (HR 1.88, 95% CI 1.40-2.54), although the RMST difference at 5 years was minimal. As cause-specific mortality was unavailable, this association might reflect underlying disease severity rather than a direct drug effect. The use of PPI was not associated with a reduced risk of clinically meaningful FVC decline, while a modest attenuation of DLCO decline was observed, and absolute progression-free differences were limited. CONCLUSIONS: PPI are commonly used in SSc characterised by a more severe multisystem phenotype. Only a marginal attenuation of ILD progression is observed, although absolute effects were small. These findings favour the generalised use of PPIs for symptomatic gastroesophageal reflux in SSc.
Reference Key
openalex_W7213636173 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Francesco Bonomi, Giulia Bandini, Corrado Campochiaro, Veronica Silvestri, Svetlana Agachi, Christina Bergmann, Oliver Distler, Brigitte Granel, Joerg Henes, Florenzo Iannone, Luca Idolazzi, Eduardo Kerzberg, Mohammad E Naffaa, Hadi Poormoghim, Mislav Radic, Marie-Elise Truchetet, Silvia Bellando Randone, Marco Matucci Cerinic, Zsuzsanna H McMahan, Michael Hughes, Eustar group
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag521
URL
https://doi.org/10.1093/rheumatology/keag521
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.